Iovance Biotherapeutics

IOVA

Market cap $803M

Overview Fund Activity

2.22 USD

-0.08

3.48%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.23

+0.01

0.45%

1 day

-3.48%

5 days

-7.11%

1 month

-11.2%

3 months

9.9%

6 months

-40.64%

Year to date

-71.5%

1 year

-78.69%

5 years

-93.77%

10 years

-71.32%

About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Employees: 838

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $3.58M | Put options by funds: $2.55M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

7.12% less ownership

Funds ownership: 73.03% [Q1] → 65.91% (-7.12%) [Q2]

17% less funds holding

Funds holding: 299 [Q1] → 248 (-51) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

52% less capital invested

Capital invested by funds: $798M [Q1] → $379M (-$418M) [Q2]

54% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 81

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

531% upside

Avg. target

$18

711% upside

High target

$20

801% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	$20	Buy Reiterated	19 Aug 2025
Wells Fargo Yanan Zhu	$14	Overweight Maintained	8 Aug 2025
Chardan Capital Geulah Livshits	$20	Buy Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about IOVA published over the past 30 days

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

Iovance Biotherapeutics to Present at Upcoming Conferences

The Motley Fool

If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today

For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).

If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today

Zacks Investment Research

IOVA Stock Drops 6% on $350M Common Stock Offering

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.

IOVA Stock Drops 6% on $350M Common Stock Offering

The Motley Fool

Why Iovance Biotherapeutics Stock Got Mashed on Monday

Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).

Why Iovance Biotherapeutics Stock Got Mashed on Monday

The Motley Fool

1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street

There's at least one good thing to say about Iovance Biotherapeutics (IOVA 5.71%), a small-cap biotech. The drugmaker is an innovative company.

1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance's common stock to 20 new, non-executive employees.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring with Q2'25 earnings, to help it extend runway to Q4'26. Upcoming data from trials of lifileucel in lung and endometrial cancer could provide upside for the stock, as could a launch of Amtagvi in Canada.

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

The Motley Fool

Why Iovance Biotherapeutics Stock Was Climbing Today

A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (IOVA 5.00%) stock higher on Tuesday. The shares were almost 6% in positive territory in the middle of today's trading session, contrasting very well with the 0.5% slide of the S&P 500 index.

Why Iovance Biotherapeutics Stock Was Climbing Today

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

The Motley Fool

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to find better returns on your money than the market's average annual gain of about 10%.

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

See News Rankings

Charts implemented using Lightweight Charts™